These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 26398375

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. 16,17-Dihydro-17b-hydroxy isomitraphylline alkaloid as an inhibitor of DPP-IV, and its effect on incretin hormone and β-cell proliferation in diabetic rat.
    Shukla A, Srinivasan BP.
    Eur J Pharm Sci; 2012 Sep 29; 47(2):512-9. PubMed ID: 22820565
    [Abstract] [Full Text] [Related]

  • 23. The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and ameliorates glomerular lesions in a rat model of type 1 diabetes.
    Marques C, Gonçalves A, Pereira PMR, Almeida D, Martins B, Fontes-Ribeiro C, Reis F, Fernandes R.
    Life Sci; 2019 Oct 01; 234():116738. PubMed ID: 31398418
    [Abstract] [Full Text] [Related]

  • 24. Glucagon, insulin and somatostatin secretion in response to sympathetic neural activation in streptozotocin-induced diabetic rats. A study with the isolated perfused rat pancreas in vitro.
    Kurose T, Tsuda K, Ishida H, Tsuji K, Okamoto Y, Tsuura Y, Kato S, Usami M, Imura H, Seino Y.
    Diabetologia; 1992 Nov 01; 35(11):1035-41. PubMed ID: 1361917
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Reduction of cardiac and renal dysfunction by new inhibitor of DPP4 in diabetic rats.
    Alves BEO, de Alencar AKN, Gamba LER, Trachez MM, da Silva JS, Araújo JSC, Montagnoli TL, Mendes LVP, Pimentel-Coelho PM, do M N Cunha V, Mendez-Otero R, Oliveira GMM, Lima LM, Barreiro EJ, Sudo RT, Zapata-Sudo G.
    Pharmacol Rep; 2019 Dec 01; 71(6):1190-1200. PubMed ID: 31669883
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The role of clusterin on pancreatic beta cell regeneration after exendin-4 treatment in neonatal streptozotocin administrated rats.
    Kaya-Dagistanli F, Ozturk M.
    Acta Histochem; 2013 Jul 01; 115(6):577-86. PubMed ID: 23351716
    [Abstract] [Full Text] [Related]

  • 29. Glucagon-Like Peptide-1 Mediates the Protective Effect of the Dipeptidyl Peptidase IV Inhibitor on Renal Fibrosis via Reducing the Phenotypic Conversion of Renal Microvascular Cells in Monocrotaline-Treated Rats.
    Xu J, Wang J, Cheng Y, Li X, He M, Zhu J, Han H, Wei G, Kong H, Xie W, Wang H, Zuo X.
    Biomed Res Int; 2018 Jul 01; 2018():1864107. PubMed ID: 29607314
    [Abstract] [Full Text] [Related]

  • 30. Liraglutide and sitagliptin counter beta- to alpha-cell transdifferentiation in diabetes.
    Tanday N, Flatt PR, Irwin N, Moffett RC.
    J Endocrinol; 2020 Apr 01; 245(1):53-64. PubMed ID: 31977315
    [Abstract] [Full Text] [Related]

  • 31. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Baranov O, Kahle M, Deacon CF, Holst JJ, Nauck MA.
    Diabetes Obes Metab; 2016 Nov 01; 18(11):1100-1109. PubMed ID: 27300579
    [Abstract] [Full Text] [Related]

  • 32. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.
    Akarte AS, Srinivasan BP, Gandhi S.
    J Diabetes Complications; 2012 Nov 01; 26(4):266-74. PubMed ID: 22626875
    [Abstract] [Full Text] [Related]

  • 33. Lack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicity.
    Fontés G, Hagman DK, Latour MG, Semache M, Poitout V.
    Diabetes Res Clin Pract; 2010 Mar 01; 87(3):322-8. PubMed ID: 20092903
    [Abstract] [Full Text] [Related]

  • 34. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
    Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, Xu G, Pu Y, Zhu Z, Xu A, Lam KS, Chen ZY, Ng CF, Yao X, Huang Y.
    Hypertension; 2012 Sep 01; 60(3):833-41. PubMed ID: 22868389
    [Abstract] [Full Text] [Related]

  • 35. The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model.
    Shang Q, Liu MK, Saumoy M, Holst JJ, Salen G, Xu G.
    Am J Physiol Gastrointest Liver Physiol; 2012 Apr 15; 302(8):G815-23. PubMed ID: 22281473
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study.
    Schopman JE, Hoekstra JBL, Frier BM, Ackermans MT, de Sonnaville JJJ, Stades AM, Zwertbroek R, Hartmann B, Holst JJ, Knop FK, Holleman F.
    Diabetes Obes Metab; 2015 Jun 15; 17(6):546-553. PubMed ID: 25694217
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Phosphate Accelerates Cellular Cholesterol Efflux in THP-1 Cells.
    Komatsu T, Abe S, Nakashima S, Sasaki K, Higaki Y, Saku K, Miura SI, Uehara Y.
    Biomolecules; 2023 Jan 24; 13(2):. PubMed ID: 36830597
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.